Overview

Founded in November 1998, Caprion Pharmaceuticals Inc. utilizes its CellCarta proteomics suite to identify the entire protein complement of organelles in normal and diseased cells to create comprehensive subcellular protein maps.

CellCarta combines proprietary cell-fractionation techniques with high-throughput protein separation, mass spectrometry and bioinformatics technologies. Information will be used to understand the protein changes underlying the pathology of diseases and to develop diagnostic and therapeutic products and treatment strategies.

The company has programs in oncology, inflammation, metabolic disorders, cardiovascular disease and central nervous system diseases, including the first diagnostic products for BSE (mad cow disease) and its human strain, Creutzfeldt-Jacob’s disease, as well as earlier-stage diagnostics and therapeutics programs in Alzheimer’s disease and amyotrophic lateral sclerosis.

In March 2001, Caprion closed a second round of financing, raising $4.1 million and bringing its total raised for the financing to $37.5 million.

Partners

Bioinformatics platform collaboration: Sun Microsystems, Oracle and CGI.

Creutzfeldt-Jacob disease human blood test and diagnostic development: Ortho-Clinical Diagnostics Inc.

Proteomics research technologies: Micromass UK Ltd.

Mad cow disease diagnostic reagents development: Idexx Laboratories Inc.